Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02213900 · ClinicalTrials.gov registry record · Phase 4
Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy
A Phase 4 study of Depression and Anxiety, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 135
- Enrollment target
- 1
- Study location
NCT02213900 is a Phase 4 study of Depression and Anxiety that has completed, run by Indiana University. The registered enrollment target is 135 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02213900, a Phase 4 study of Depression and Anxiety, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 135 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to investigate the effectiveness of a preventative low-dose of Haloperidol to prevent delirium in patients undergoing a esophagectomy, pneumonectomy or thoracotomy. Delirium is state of severe confusion and some symptoms include: * Cannot think clearly * Have trouble paying attention * Have a hard time understanding what is going on around them * May see or hear things that are not there. These things seem very real to them.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Haloperidol
Study Locations (1)
Indiana
- University Hospital - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2013-09 |
| Est. Completion | 2015-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02213900
The ClinicalTrials.gov registry entry for NCT02213900 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (83% lower). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02213900 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT02213900 about?
NCT02213900 is a clinical study titled "Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy". The purpose of this study is to investigate the effectiveness of a preventative low-dose of Haloperidol to prevent delirium in patients undergoing a esophagectomy, pneumonectomy or thoracotomy. Delirium is state of severe confusion and some symptoms include: * Cannot think clearly * Have trouble p...
What is the current status of trial NCT02213900?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 135 participants. The study started on 2013-09. Estimated completion is 2015-12.
What conditions does trial NCT02213900 study?
This clinical trial studies the following conditions: Depression, Anxiety, Post Traumatic Stress Disorder, Cognitive Impairment, Delirium.
What interventions are being tested in trial NCT02213900?
The interventions under investigation include: Placebo (DRUG), Haloperidol (DRUG).
Who is sponsoring clinical trial NCT02213900?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02213900 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Identifying and Treating Depression in the Orthopaedic Trauma Population
RECRUITING · Phase 4
-
Dopaminergic Therapy for Anhedonia - 2
RECRUITING · Phase 4
-
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
RECRUITING · Phase 4
-
Buspirone and Melatonin for Depression Following Traumatic Brain Injury
RECRUITING · Phase 4
-
Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression
RECRUITING · Phase 4
-
Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.